Date: 2016-11-07
Type of information: Resignation
Compound:
Company: Molecular Partners (Switzerland)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details: * On November 7, 2016. Molecular Partners announced that Christian Zahnd, Ph.D., co-founder and Chief Executive Officer (CEO) of the company, resigned due to health reasons. Christian Zahnd will remain a member of the Board of Directors. The Board of Directors appointed Patrick Amstutz, Ph.D., co-founder, Chief Business Officer and Chief Operating Officer, as acting CEO. Working with Joern Aldag, Chairman of the board of directors of Molecular Partners, Patrick Amstutz took over Christian Zahnd’s responsibilities for five months when he was on medical leave in 2015 and successfully led the Company during Christian Zahnd’s absence.
While the Board of Directors appointed Patrick Amstutz as acting CEO, it is evaluating the most suitable successor to Christian Zahnd from within or outside the organization.
Financial terms:
Latest news:
